ArticleBritish journal of pharmacology1994
Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats.
Article in British journal of pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Effect of endothelin-1 on the blood pressure response to acute hypoxia and hyperoxia in healthy young men.Physiological reports · 2024Trial
- Endothelin.Pharmacological reviews · 2016Review
- Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.Biochemical pharmacology · 2012Review
- Enhanced expressions of endothelin-converting enzyme and endothelin receptors in human colonic tissues of Crohn's disease.Journal of clinical biochemistry and nutrition · 2008Article
- Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo.British journal of pharmacology · 2005Article
- Effects of the novel selective endothelin ET(A) receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats.British journal of pharmacology · 2001Article
- Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats.British journal of pharmacology · 2000Article
- Reversal of the vasoconstrictor step of hyperacute xenogeneic rejection of the liver by endothelin antagonists.British journal of pharmacology · 2000Article
- Role for endogenous endothelin in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats.British journal of pharmacology · 2000Article
- Understanding gastrointestinal perfusion in critical care: so near, and yet so far.Critical care (London, England) · 2000Review
- Article
- Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock.British journal of pharmacology · 1996Article
- Effects of the non-peptide, non-selective endothelin antagonist, bosentan, on regional haemodynamic responses to NG-monomethyl-L-arginine in conscious rats.British journal of pharmacology · 1996Article
- Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.British journal of pharmacology · 1995Article
- Enhancement of the hypotensive and vasodilator effects of endotoxaemia in conscious rats by the endothelin antagonist, SB 209670.British journal of pharmacology · 1995Article
- Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.British journal of pharmacology · 1995Article
- In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.British journal of pharmacology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Regional haemodynamic responses to endothelin (ET)-1, -2 and -3 and big ET-1 (all at 500 pmol kg-1) were assessed in the same conscious Long Evans rats (n = 8) in the absence or presence of the mixed ETA-, ETB-receptor antagonist, Ro 47-0203 (bosentan; 30 mg kg-1). 2. Bosentan blocked the initial depressor, tachycardic and hindquarters hyperaemic vasodilator effects of ET-1, -2 and -3, and substantially curtailed the primary renal and secondary hindquarters vasoconstrictor responses. Bosentan did not inhibit the initial mesenteric vasoconstrictor action of ET-1, but reduced the duration of the later mesenteric vasoconstriction. In contrast, bosentan delayed the rate of onset, and reduced the duration, of the mesenteric vasoconstrictor actions of ET-2 and ET-3. The most likely explanation of this finding is that ET-1, but not ET-2 or ET-3, triggered a covert mesenteric vasodilator mechanism which was antagonized by bosentan. 3. Bosentan blocked all the effects of big ET-1, and, in a separate group of rats (n = 7), blocked all the haemodynamic effects of a lower dose of ET-1 (50 pmol kg-1), with the exception of a slight mesenteric vasoconstriction. 4. The most straightforward explanation of the results is that the major haemodynamic effects of ET-1, -2 and -3, and all the effects of big ET-1, are mediated through ETA- and/or ETB-receptors that are effectively antagonized by bosentan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.